沙库巴曲缬沙坦在终末期肾病中的心血管获益与安全性系统综述
该系统综述纳入12项研究共799例透析的终末期肾病患者,评估沙库巴曲缬沙坦对比标准治疗的心血管获益与安全性。结果显示沙库巴曲缬沙坦组左心室射血分数(LVEF)总体改善,合并均数差6.58%(95%CI:1.86,11.29);LVEF<50%者改善更显著,MD 12.42%(95%CI:9.39,15.45);LVEF>50%者无统计学显著效应。高钾血症和低血压发生率无差异,未报告血管性水肿。
要点
- 沙库巴曲缬沙坦可改善透析的ESKD患者LVEF,尤其HFrEF和HFmrEF人群。
- HFpEF(LVEF>50%)患者未见统计学显著LVEF改善。
- 高钾血症、低血压及血管性水肿风险与标准治疗无显著差异。
核心结论
- 沙库巴曲缬沙坦可能改善透析的ESKD合并HFrEF或HFmrEF患者的LVEF,且未增加高钾血症、低血压或血管性水肿风险。
- 安全性分析基于观察性研究,因果推断受限。
研究设计与样本
- 系统综述,检索Embase、MEDLINE和Cochrane数据库。
- 纳入12项研究,共799例符合条件的ESKD透析患者。
- 采用随机效应模型和通用逆方差法评估结局。
主要发现
- 沙库巴曲缬沙坦组LVEF总体改善,合并MD 6.58%(95%CI:1.86,11.29)。
- LVEF<50%患者LVEF显著改善,MD 12.42%(95%CI:9.39,15.45)。
- LVEF>50%患者LVEF无统计学显著改善,MD 2.6%(95%CI:1.15,6.35)。
- HFrEF患者LVEF显著改善,MD 13.8%(95%CI:12.04,15.82)。
- 高钾血症合并OR 0.72(95%CI:0.38,1.36),低血压合并RR 1.03(95%CI:0.36,2.98),未报告血管性水肿。
临床怎么用
- 对透析的ESKD合并HFrEF或HFmrEF患者,可考虑使用沙库巴曲缬沙坦以改善LVEF。
- 用药期间仍需监测高钾血症和低血压,尽管本综述未显示风险增加。
局限性
- 安全性分析基于观察性研究,证据稳健性有限,难以确立因果关系。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Patients with end-stage kidney disease (ESKD) frequently develop heart failure, contributing to high mortality. Limited data exist on cardiovascular benefits and safety of sacubitril-valsartan in this population. Our systematic review aims to evaluate the efficacy and safety of sacubitril-valsartan versus standard care in patients with ESKD who are on dialysis. METHODS: We conducted a search in Embase, MEDLINE, and Cochrane databases to identify relevant studies and assessed outcomes using random-effect model and generic inverse variance approach. RESULTS: Analysis of 12 studies involving 799 eligible patients with ESKD revealed improvement in left ventricular ejection fraction (LVEF) with sacubitril-valsartan compared to a control group with pooled mean difference (MD) 6.58% (95% confidence interval [CI]: 1.86, 11.29). LVEF significantly improved in patients with LVEF <50% (heart failure with reduced ejection fraction [HFrEF] and heart failure with moderately reduced ejection fraction [HFmrEF]) with MD 12.42% (95% CI: 9.39, 15.45). However, patients with LVEF >50% (heart failure with preserved ejection fraction [HFpEF]) did not exhibit statistically significant effect, MD 2.6% (95% CI: 1.15, 6.35). Sacubitril-valsartan significantly enhanced LVEF in patients with HFrEF, with MD 13.8% (95% CI: 12.04, 15.82). Safety analysis indicated no differences in incidence of hyperkalemia (pooled odds ratio [OR] 0.72; 95% CI: 0.38, 1.36) or hypotension (pooled risk ratio [RR] 1.03; 95% CI: 0.36, 2.98). No cases of angioedema were reported. However, safety analysis relies on evidence of limited robustness due to the observational nature of the studies. CONCLUSION: Our systematic review suggests that sacubitril-valsartan benefits patients with ESKD with HFrEF and HFmrEF by improving LVEF without increasing the risk of hyperkalemia, hypotension, or angioedema compared to standard care. However, safety analysis based on observational studies inherently has limitations for establishing causal relationships.
引用
- Charkviani M, Krisanapan P, Thongprayoon C, et al. Systematic Review of Cardiovascular Benefits and Safety of Sacubitril-Valsartan in End-Stage Kidney Disease. Kidney Int Rep. 2023. PMID: 38312794. doi:10.1016/j.ekir.2023.10.008
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。